|
||||
 |
||||
Dockets
Management
|
||||
|
Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee
April 25, 2006 Briefing Information Cellegy Pharmaceuticals, Inc. Cellegesic™ Nitroglycerin Ointment 0.4% NDA 21-359 Disclaimer The statements contained in this document(s) are those of the product's
sponsor, not FDA, and FDA does not necessarily agree with
the sponsor's statements. FDA has not made a final determination
about the safety or effectiveness of the product described
in this document.
Food and Drug Administration Briefing Document NDA 21-359 1. Division Director’s
Questions to the Committee 2. Division Director
Memo 12/20/04 3. Division Director
Memo 12/22/04 4. Division Director
Memo 12/23/04 5. Medical/Statistical
Review 02/27/02 6. Division Director
Memo 04/29/02 9. Medical Review
of sponsor’s response to NA letter 05/26/05 Page last updated
April 24, 2006
kk |
